RxSight (RXST) Q1 2025: LAL Revenue Rises 37% as Macro and Competitive Friction Delays Recovery
RxSight’s first top-line miss since IPO underscores how macro headwinds and competitive trialing are reshaping premium IOL adoption curves. Margin strength and robust LAL revenue growth were offset by softer procedure volumes and slower ramp at new sites, with management reiterating guidance but signaling that reacceleration is now a second-half story. Investors should watch for the impact of new software, commercial support, and international launches as the premium lens market enters a more crowded, value-driven phase.
Summary
- Premium Market Saturation Debate Intensifies: Slower LAL ramp and competitive trialing pressure near-term growth.
- Margin Expansion Driven by Product Mix: LAL’s rising share boosts gross margin, but volume leverage may fade as production normalizes.
- Second-Half Recovery Narrative: Management pivots focus to H2 as commercial and clinical initiatives are deployed.
Performance Analysis
RxSight delivered 28% revenue growth year-over-year, but the quarter marked its first revenue shortfall since going public, as both macroeconomic uncertainty and competitive trialing weighed on premium cataract procedure volumes. LAL, light adjustable lens, revenue climbed 37% YoY and accounted for 72% of total revenue, up from 67% a year ago, reflecting both higher unit sales and a favorable shift in product mix. LDD, light delivery device, unit sales grew 11% YoY, but sequentially declined 12% from a seasonally strong Q4, with the installed base reaching 1,044 units (up 43% YoY).
Gross margin expanded meaningfully to 74.8%, driven by higher LAL revenue mix and fixed cost leverage from last year’s LAL Plus inventory build. However, the company flagged that this margin tailwind will moderate as production is right-sized to revised demand expectations. Operating expenses rose in line with planned investment in clinical education and marketing, and the non-GAAP net loss narrowed significantly. Cash and equivalents increased to $229.3 million, supporting ongoing commercial and R&D investment.
- Premium Lens Mix Shift: LAL’s share of revenue rose to 72%, driving margin expansion and signaling deepening adoption among new and existing sites.
- Procedure Volume Friction: Macro-driven patient deferrals and competitive trialing, especially in multifocal IOLs, slowed LAL per LDD procedure growth for the first time.
- Cost Structure Leverage: Fixed cost absorption from prior inventory build temporarily boosted gross margin, but normalization is expected as production slows.
While the premium lens growth engine remains intact, near-term execution is challenged by both external demand shocks and the evolving competitive landscape, requiring a heavier lift from commercial and educational initiatives to reignite growth momentum in the back half of the year.
Executive Commentary
"The first quarter brought an unusual combination of macroeconomic headwinds and competitive disruptions that led to our first top-line miss since becoming a public company in Q3 2021."
Dr. Ron Kurtz, President and Chief Executive Officer
"We are maintaining our gross margin guidance of 71 to 73% despite gross margin of 74.8% reported in the first quarter. Because a significant portion of our LAL cost of goods sold is fixed, the anticipated benefit to gross margin from higher production LAL volume 2025 will now be reduced given the revised revenue outlook."
Shelley Tunin, Chief Financial Officer
Strategic Positioning
1. Competitive Landscape: Multifocal Commoditization and Trialing
RxSight faces a more crowded premium IOL market, with customers citing that major multifocal offerings are now "essentially equivalent" across manufacturers. Competitive trialing—where surgeons sample new multifocal IOLs—has led to temporary procedure deferrals and diluted differentiation, particularly as Alcon and Bausch & Lomb ramp new launches. This dynamic is expected to persist through Q2, but management believes it will normalize, with LAL positioned as a differentiated alternative amid commoditization.
2. Macro Sensitivity: Deferral and Trade-Down Behavior
Patient demand proved highly elastic, with RxSight’s customer survey and third-party data confirming that negative wealth effects and macro uncertainty drove a trade-down from premium to lower-cost monofocal and toric lenses. Since 75% of LAL patients are drawn from this upgrade cohort, macro headwinds had a direct impact. While stabilization was seen late in April, the company expects ongoing friction until patient confidence rebounds.
3. Commercial Execution: Education and Workflow Integration
Operational focus is shifting to same-store growth, with targeted clinical education, workflow optimization, and marketing support aimed at overcoming workload barriers and practice inertia. Management acknowledges that staffing shortages and new-technology learning curves remain hurdles, and is responding with enhanced training, best-practice dissemination, and the launch of new software features (notably Sphera Collaboration and procedure monitoring) to embed LAL more deeply in clinical routines.
4. International Expansion: Regulatory Progress, Selective Entry
RxSight continues to advance global market access, securing regulatory approvals in South Korea and the EU, with the UK expected in Q2. Entry strategies are tailored by market, often using distributors where required. While OUS premium lens penetration is lower than in the US, management views select markets (especially Korea, Germany, and the UK) as high-potential footholds, though near-term revenue impact will be modest as adoption ramps from a low base.
5. Business Model Evolution: Third-Party Treatment Centers
The emergence of third-party LDD service centers, akin to the LASIK center model, is a nascent but promising channel to expand access and utilization—especially for surgeons unwilling to purchase capital equipment. While still early, this model could help RxSight address smaller or more risk-averse practices, smoothing adoption curves and potentially accelerating premium IOL penetration over time.
Key Considerations
This quarter marks a strategic inflection point for RxSight, as leadership pivots from a pure growth narrative to a more nuanced playbook balancing macro, competitive, and operational realities.
Key Considerations:
- Premium Mix as Margin Lever: LAL’s rising share of revenue is the primary driver of gross margin expansion, but sustainability depends on procedure volume recovery and continued adoption at both new and existing sites.
- Commercial Investment Timing: Management is front-loading clinical education and marketing spend to drive second-half growth, with the pace of recovery hinging on both external demand stabilization and internal execution.
- International as Long-Term Optionality: New approvals in South Korea and Europe offer incremental growth vectors, but will require market development and KOL engagement before becoming material contributors.
- Practice Workflow as Adoption Bottleneck: Staffing shortages and post-operative adjustment complexity remain friction points, addressed through enhanced training and best-practice sharing.
- Third-Party Access Models: Early traction in LDD service centers could broaden RxSight’s reach, but the model’s scalability and economics remain to be proven.
Risks
Persistent macroeconomic headwinds, especially those impacting elective spending among the 65-plus cohort, could delay premium lens recovery and mute the impact of commercial initiatives. Competitive trialing, particularly from new multifocal launches, risks prolonging procedure deferrals and pricing pressure. Operationally, slower ramp at new sites and ongoing workflow challenges could restrain same-store growth, while international expansion carries regulatory, reimbursement, and channel execution risks. Investors should monitor for signs that H2 volume recovery is materializing as management expects.
Forward Outlook
For Q2 2025, RxSight guided to:
- No explicit quarterly revenue target, but management cautioned that Q2 will not see a typical seasonal uptick, with most LAL growth expected in H2.
- Gross margin expected to moderate from Q1’s elevated level, landing in the 71-73% range for the full year.
For full-year 2025, management reiterated guidance:
- Revenue of $160 to $175 million (14-25% YoY growth), assuming H2 procedure recovery.
- Gross margin of 71-73%.
- Operating expenses of $150 to $160 million, with targeted investment in clinical education, marketing, and R&D.
Management highlighted:
- Second-half recovery in LAL procedure volume as macro and competitive trialing normalize.
- Early signs of stabilization in late April, but ongoing caution for Q2 given lingering uncertainty.
Takeaways
RxSight’s premium lens growth engine remains differentiated, but near-term execution will be tested by macro and competitive friction.
- Margin Expansion Hinges on Premium Mix: LAL’s rising share is accretive, but requires sustained volume growth to offset fixed cost leverage normalization as production is right-sized.
- Second-Half Growth is a Must-Watch: Management’s guidance and investment thesis now rest on a back-half rebound—investors should track procedure trends, new site ramp, and competitive trialing closely.
- International and Access Models Offer Long-Term Upside: Regulatory wins and third-party LDD centers could unlock new growth vectors, but will take time to scale and prove out.
Conclusion
RxSight’s Q1 print highlights a business at the intersection of premium technology differentiation and market reality, with macro and competitive forces driving near-term turbulence. The company’s ability to deliver on its second-half recovery narrative—through targeted commercial execution and innovation—will be the key test for both management and investors in 2025.
Industry Read-Through
The premium cataract surgery market is entering a phase of heightened competition and value focus, with commoditization of multifocal IOLs blurring differentiation and increasing the importance of workflow integration and patient education. Macro-driven patient deferral and trade-down behavior are likely to impact all premium device makers, while the shift toward open-access models (such as third-party treatment centers) could reshape capital equipment adoption curves. For medtech peers, the RxSight narrative underscores the need for commercial agility and product innovation to sustain premium pricing and margin expansion as market cycles evolve.